Heron Therapeutics Inc HRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.38
- Day Range
- $0.39–0.41
- 52-Week Range
- $0.38–2.30
- Bid/Ask
- $0.39 / $0.40
- Shares Outstanding
- 189.28M
- Market Cap
- $73.31M
- Volume/Avg
- 2,246 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 128
- Website
- https://www.herontx.com
Valuation
|
Metric
|
HRTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.33 |
Price/Sales | 0.44 |
Price/Cash Flow | — |
Price/Earnings
HRTX
Financial Strength
|
Metric
|
HRTX
|
|---|---|
Quick Ratio | 1.42 |
Current Ratio | 2.53 |
Interest Coverage | — |
Quick Ratio
HRTX
Profitability
|
Metric
|
HRTX
|
|---|---|
Return on Assets (Normalized) | −3.61% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −5.79% |
Return on Assets
HRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Yvcw | — | |||
| Athersys Inc
ATHXQ
| — | Bdqpn | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yndqggf | Jctbm | $116B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fqwzhjfkr | Zvsgg | $64B | |||
| argenx SE
ARGNF
| — | Xmlyc | $56B | |||
| argenx SE ADR
ARGX
| Jzvsbvr | Tclc | $56B | |||
| UCB SA
UCBJF
| — | Jkd | $56B | |||
| UCB SA ADR
UCBJY
| — | Kqhf | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fqbmfbdh | Hdqpmsc | $38B | |||
| CSL Ltd
CMXHF
| — | Chpwsx | $36B |
United States